[go: up one dir, main page]

CR9383A - Metodos para fabricar compuestos mejorados farmacocineticamente que comprenden residuos o grupos funcionales y composiciones farmaceuticas que comprenden dichos compuestos - Google Patents

Metodos para fabricar compuestos mejorados farmacocineticamente que comprenden residuos o grupos funcionales y composiciones farmaceuticas que comprenden dichos compuestos

Info

Publication number
CR9383A
CR9383A CR9383A CR9383A CR9383A CR 9383 A CR9383 A CR 9383A CR 9383 A CR9383 A CR 9383A CR 9383 A CR9383 A CR 9383A CR 9383 A CR9383 A CR 9383A
Authority
CR
Costa Rica
Prior art keywords
compounds
methods
pharmaceutical compositions
pharmacocinetically
functional groups
Prior art date
Application number
CR9383A
Other languages
English (en)
Inventor
Frances Lund
David Duffy
Michael Grogan
Steven Kates
Original Assignee
Surface Logix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surface Logix Inc filed Critical Surface Logix Inc
Publication of CR9383A publication Critical patent/CR9383A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion se relaciona con metodos para modular las propiedades farmacocineticas y / o farmacodinamicas de un compuesto uniendo por lo menos una unidad o grupo funcional al compuesto, mejorando asi sus caracteristicas de union no especifica y /o sus prioridades farmacocineticas. Se proporcionan compuestos que comprenden por ,lo menos un residuo funcional, asi como composiciones farmaceuticas que comprenden esos compuestos.
CR9383A 2005-02-18 2007-09-14 Metodos para fabricar compuestos mejorados farmacocineticamente que comprenden residuos o grupos funcionales y composiciones farmaceuticas que comprenden dichos compuestos CR9383A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65451905P 2005-02-18 2005-02-18

Publications (1)

Publication Number Publication Date
CR9383A true CR9383A (es) 2008-06-19

Family

ID=36917158

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9383A CR9383A (es) 2005-02-18 2007-09-14 Metodos para fabricar compuestos mejorados farmacocineticamente que comprenden residuos o grupos funcionales y composiciones farmaceuticas que comprenden dichos compuestos

Country Status (19)

Country Link
US (1) US20110172422A1 (es)
EP (1) EP1848437A4 (es)
JP (1) JP2008530246A (es)
KR (1) KR20080015391A (es)
CN (1) CN101287468A (es)
AU (1) AU2006213984A1 (es)
BR (1) BRPI0608356A2 (es)
CA (1) CA2598270A1 (es)
CR (1) CR9383A (es)
EA (1) EA200701752A1 (es)
IL (1) IL185347A0 (es)
MX (1) MX2007010142A (es)
NI (1) NI200700211A (es)
NO (1) NO20074741L (es)
NZ (1) NZ560962A (es)
SG (1) SG174829A1 (es)
UA (1) UA95604C2 (es)
WO (1) WO2006089275A2 (es)
ZA (1) ZA200707506B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
US20100324037A1 (en) 2006-08-24 2010-12-23 Surface Logix, Inc. Pharmacokinetically improved compounds
EP3360962A1 (en) * 2017-02-14 2018-08-15 Technische Universität Dortmund Synthesis of dna-encoded libraries by micellar catalysis

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) * 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453257A (en) * 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453259A (en) * 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5359115A (en) * 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5480971A (en) * 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US5440016A (en) * 1993-06-18 1995-08-08 Torrey Pines Institute For Molecular Studies Peptides of the formula (KFmoc) ZZZ and their uses
US5362899A (en) * 1993-09-09 1994-11-08 Affymax Technologies, N.V. Chiral synthesis of alpha-aminophosponic acids
CA2309332C (en) * 1997-11-12 2002-12-03 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US5958886A (en) * 1998-01-13 1999-09-28 Sigma-Tau Pharmaceuticals, Inc. Carnitine-containing peptides and a method for using the same
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
WO2001047928A2 (de) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Imidazo 1,3,5 triazinone und ihre verwendung
EP1261609B1 (de) * 1999-12-24 2004-11-03 Bayer HealthCare AG Triazolotriazinone und ihre verwendung
US6794387B2 (en) * 2001-03-28 2004-09-21 Pfizer Inc. Pharmaceutically active compounds
EA018668B1 (ru) * 2005-02-18 2013-09-30 Сурфейс Логикс Инк. Фармакокинетически улучшенные соединения

Also Published As

Publication number Publication date
MX2007010142A (es) 2007-12-07
KR20080015391A (ko) 2008-02-19
NZ560962A (en) 2011-12-22
EA200701752A1 (ru) 2008-04-28
NO20074741L (no) 2007-11-14
IL185347A0 (en) 2008-02-09
JP2008530246A (ja) 2008-08-07
EP1848437A4 (en) 2012-04-25
US20110172422A1 (en) 2011-07-14
WO2006089275A2 (en) 2006-08-24
WO2006089275A3 (en) 2006-12-21
CN101287468A (zh) 2008-10-15
NI200700211A (es) 2008-07-24
BRPI0608356A2 (pt) 2009-12-29
UA95604C2 (ru) 2011-08-25
CA2598270A1 (en) 2006-08-24
EP1848437A2 (en) 2007-10-31
ZA200707506B (en) 2009-08-26
SG174829A1 (en) 2011-10-28
AU2006213984A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
BRPI0711889B8 (pt) método para produção de sinvastatina, composição de matéria, método para fabricação de huvastatina, método para fabricação de sinvastatina, e método para fabricação de uma composição de matéria de sinvastatina ou huvastatina
EA201070015A1 (ru) Композиции, содержащие антитело
CO6280399A2 (es) Peptidil nitrilos y uso de los mismos como inhibidores de peptidil peptidasa i
DE602007012559D1 (de) H die schleimhaut
ATE451421T1 (de) Polypropylenzusammensetzung enthaltend ein propylenhomopolymer
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
HN2006011218A (es) Composiciones de tigeciclina y métodos de preparación
ECSP088854A (es) Moduladores bencimidazolicos de vr1
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
CR11136A (es) INHIBICION DE ARNi DE EXPRESION DE ALFA-ENaC
CL2008000789A1 (es) Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras.
DE602005022319D1 (de) Modifizierte pyrimidin-glucocorticoid-rezeptor-modulatoren
WO2008118626A3 (en) Inhibitors of jnk and methods for identifying inhibitors of jnk
CR9934A (es) Composiciones de asilamiento libres de plomo mejoradas que contienen polimeros de metaloceno
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
EA201300338A1 (ru) Пестицидная и паразитицидная смесь и композиция, которая включает новую кристаллическую модификацию фипронила
MEP35508A (bs) Poboljšani uređaj za distribuciju
CL2007001919A1 (es) Compuestos derivados de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas; composicion farmaceutica que comprende a dichos compuestos, utiles como anticonceptivos.
WO2011033064A3 (en) Disulfo-type fluorescent whitening agent compositions
EA200701462A1 (ru) Распадающаяся при пероральном приёме композиция оланзапина или донепезила
TW200621313A (en) Pharmaceutical compositions
GT200600222A (es) Tigeciclina y metodos para preparar 9-aminominociclilna
HN2009000856A (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
CR9383A (es) Metodos para fabricar compuestos mejorados farmacocineticamente que comprenden residuos o grupos funcionales y composiciones farmaceuticas que comprenden dichos compuestos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)